psychology beginner 10 sample questions

Psychopharmacology MCQ Practice Test

Medication treatments for mental conditions

Q1. A patient with treatment-resistant major depressive disorder is being considered for a trial of ketamine infusions. Which of the following mechanisms of action is thought to contribute to ketamine's antidepressant effects?

Explanation: Ketamine's antidepressant effects are thought to be mediated by its ability to increase the expression of brain-derived neurotrophic factor (BDNF) in the brain, which promotes neural plasticity and survival. While ketamine also has effects on glutamate release and the default mode network, these are not thought to be the primary mechanisms contributing to its antidepressant effects.

Q2. Which of the following is a characteristic of the noradrenergic hypothesis of depression, particularly in relation to the use of tricyclic antidepressants?

Explanation: The noradrenergic hypothesis of depression suggests that decreased noradrenergic activity contributes to depressive symptoms. Tricyclic antidepressants (TCAs) are thought to exert their therapeutic effects by enhancing noradrenergic neurotransmission, which can be achieved through increased release of norepinephrine or decreased reuptake of norepinephrine.

Q3. A patient with treatment-resistant major depressive disorder is started on a combination of escitalopram and aripiprazole. Which of the following is a potential mechanism by which aripiprazole may augment the antidepressant effects of escitalopram?

Explanation: Aripiprazole augments SSRIs in resistant depression mainly through its D2 and 5-HT1A partial agonism (dopamine "stabilisation") plus 5-HT2A antagonism. Reuptake inhibition is how SSRIs and SNRIs work, MAO inhibition defines MAOIs, and full D2 blockade typifies typical antipsychotics such as haloperidol. The keyed "reduces serotonergic syndrome" rationale was not the augmentation mechanism.

Q4. A patient with treatment-resistant major depressive disorder is being considered for a trial of ketamine infusions. Which of the following is a potential mechanism by which ketamine exerts its rapid antidepressant effects?

Explanation: Ketamine's rapid antidepressant effects are thought to be mediated by its ability to block NMDA receptors, leading to increased expression of AMPA receptors and enhanced excitatory neurotransmission. This, in turn, can facilitate neural plasticity and promote the growth of new neurons, leading to improved mood and reduced depressive symptoms.

Q5. Which of the following is a characteristic of the "therapeutic window" of the antipsychotic drug risperidone?

Explanation: The therapeutic window of a drug refers to the range of doses at which the drug is effective for treating a particular condition, while minimizing the risk of adverse effects. In the case of risperidone, this window is typically associated with the treatment of schizophrenia, where the drug can effectively manage symptoms without causing significant side effects.

Q6. Which of the following dopamine receptor subtypes is primarily involved in the therapeutic effects of amisulpride, a second-generation antipsychotic used in the treatment of schizophrenia?

Explanation: Amisulpride is a selective dopamine D2/D3 receptor antagonist, and its therapeutic effects are primarily mediated through its action on D2 receptors, which are involved in the regulation of motor function and cognitive processing. While D2 receptors are primarily responsible for the therapeutic effects, amisulpride also has some affinity for D3 receptors, which may contribute to its side effect profile.

Q7. A patient with treatment-resistant depression is being considered for a combination of escitalopram and aripiprazole. Which of the following is a potential mechanism by which aripiprazole may augment the antidepressant effects of escitalopram?

Explanation: Aripiprazole, a partial agonist at the D2 receptor, has been shown to activate the mTOR pathway, which may enhance neuroplasticity and contribute to its antidepressant effects when combined with an SSRI like escitalopram. This mechanism is distinct from its partial agonism at the D2 receptor, which is more relevant to its antipsychotic effects.

Q8. A 35-year-old woman with a history of major depressive disorder is started on a combination of fluoxetine and bupropion. Which of the following is the most likely reason for adding bupropion to her treatment regimen?

Explanation: Bupropion is often added to SSRIs like fluoxetine to enhance their antidepressant effects by targeting the noradrenergic system, which is thought to be involved in the pathophysiology of depression. This combination is often used in treatment-resistant depression.

Q9. A patient with treatment-resistant depression is being considered for a clinical trial of a novel antidepressant that targets the β-endorphin system. Which of the following is a potential mechanism by which this medication may exert its therapeutic effects?

Explanation: The β-endorphin system plays a crucial role in modulating mood and emotional processing. Targeting this system with a novel antidepressant may provide a unique therapeutic mechanism for treatment-resistant depression.

Q10. A patient with treatment-resistant depression is prescribed a medication that targets the 5-HT1A receptor. Which of the following is a potential side effect of this medication?

Explanation: Medications that target the 5-HT1A receptor, such as buspirone, can cause vasodilation and hypotension, leading to dizziness upon standing. This is a common side effect of these medications.

That was just a sample. Sign up to unlock the full question bank with timed tests and certificates.

Sign Up Free
Psychopharmacology MCQ Practice Test | Mind Hustle